Form SC 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0001104659-24-098630
Filing Date
2024-09-10
Accepted
2024-09-10 16:51:38
Documents
1
Group Members
DECHENG ANBIO LTDDECHENG CAPITAL GLOBAL HEALTHCARE FUND (MASTER), LPDECHENG CAPITAL GLOBAL HEALTHCARE GP, LLCDECHENG CAPITAL MANAGEMENT III (CAYMAN), LLCXIANGMIN CUI

Document Format Files

Seq Description Document Type Size
1 SC 13D tm2423710d1_sc13d.htm SC 13D 158226
  Complete submission text file 0001104659-24-098630.txt   160155
Mailing Address UGLAND HOUSE, PO BOX 309 GRAND CAYMAN E9 KY1-1104
Business Address UGLAND HOUSE, PO BOX 309 GRAND CAYMAN E9 KY1-1104 345-949-8066
Decheng Capital China Life Sciences USD Fund III, L.P. (Filed by) CIK: 0001736814 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SC 13D

Mailing Address 357 TEHAMA STREET, FLOOR 3 SAN FRANCISCO CA 94103
Business Address 357 TEHAMA STREET, FLOOR 3 SAN FRANCISCO CA 94103 (415) 754-3517
Nuvation Bio Inc. (Subject) CIK: 0001811063 (see all company filings)

EIN.: 850862255 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-91681 | Film No.: 241290608
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)